Další formáty:
BibTeX
LaTeX
RIS
@article{1215279,
author = {Souied, Eric and Devin, Francois and MaugetandFaysse, Martine and Kolář, Petr and WolfandSchnurrbusch, Ute and Framme, Carsten and Gaucher, David and Querques, Giuseppe and Stumpp, Michael and Wolf, Sebastian},
article_location = {New York},
article_number = {4},
doi = {http://dx.doi.org/10.1016/j.ajo.2014.05.037},
keywords = {Ranibizumab; Therapy; Darpins; Anchor; Eye; Epidemiology},
language = {eng},
issn = {0002-9394},
journal = {American journal of ophthalmology},
title = {Treatment of Exudative Age-Related Macular Degeneration with a Designed Ankyrin Repeat Protein that Binds Vascular Endothelial Growth Factor: a Phase I/II Study},
url = {http://dx.doi.org/10.1016/j.ajo.2014.05.037},
volume = {158},
year = {2014}
}
TY - JOUR
ID - 1215279
AU - Souied, Eric - Devin, Francois - Mauget-Faysse, Martine - Kolář, Petr - Wolf-Schnurrbusch, Ute - Framme, Carsten - Gaucher, David - Querques, Giuseppe - Stumpp, Michael - Wolf, Sebastian
PY - 2014
TI - Treatment of Exudative Age-Related Macular Degeneration with a Designed Ankyrin Repeat Protein that Binds Vascular Endothelial Growth Factor: a Phase I/II Study
JF - American journal of ophthalmology
VL - 158
IS - 4
SP - 724-732
EP - 724-732
PB - Elsevier Science Inc.
SN - 00029394
KW - Ranibizumab
KW - Therapy
KW - Darpins
KW - Anchor
KW - Eye
KW - Epidemiology
UR - http://dx.doi.org/10.1016/j.ajo.2014.05.037
N2 - PURPOSE: To evaluate the safety, tolerability and bioactivity of ascending doses of MP0112, a designed ankyrin repeat protein (DARPin) that binds with high affinity to vascular endothelial growth factor-A (VEGF-A), in treatment-naive patients with exudative age-related macular degeneration (AMD). DESIGN: Phase I/II, open-label, multicenter, dose-escalation study. METHODS: Patients were to receive a single intravitreal injection of MP0112 at doses ranging from 0.04 to 3.6 mg and be monitored for 16 weeks for safety, efficacy, pharmacokinetics, and dose response. RESULTS: Altogether, 32 patients received a single injection of MP0112. The maximum tolerated dose was 1.0 mg because of a case of endophthalmitis in the 2.0 mg cohort. Drug-related adverse events were reported by 13 (41%) of 32 patients; they included ocular inflammation in 11 patients (7 mild, 4 moderate in severity). Visual acuity scores were stable or improved compared with baseline for >= 4 weeks following injection; both retinal thickness and fluorescein angiography leakage decreased in a dose-dependent manner. Rescue therapy was administered to 20 (91%) of 22 patients who received 0.04-0.4 mg MP0112 compared with 4 of 10 (40%) patients who received 1.0 or 2.0 mg. Of patients in the higher-dose cohorts who did not require rescue treatment, 83% (5/6) maintained reductions in central retinal thickness through week 16. CONCLUSIONS: A single injection of 1.0 or 2.0 mg MP0112 resulted in mean decreases in retinal thickness and leakage area despite ocular inflammation. larger-scale studies are warranted to confirm these observations. (C) 2014 The Authors. Published by Elsevier Inc. All rights reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
ER -
SOUIED, Eric, Francois DEVIN, Martine MAUGET-FAYSSE, Petr KOLÁŘ, Ute WOLF-SCHNURRBUSCH, Carsten FRAMME, David GAUCHER, Giuseppe QUERQUES, Michael STUMPP a Sebastian WOLF. Treatment of Exudative Age-Related Macular Degeneration with a Designed Ankyrin Repeat Protein that Binds Vascular Endothelial Growth Factor: a Phase I/II Study. \textit{American journal of ophthalmology}. New York: Elsevier Science Inc., 2014, roč.~158, č.~4, s.~724-732. ISSN~0002-9394. Dostupné z: https://dx.doi.org/10.1016/j.ajo.2014.05.037.
|
